RxDoctor Payments Data

Michael Sorrell, MD

Neurology · Springfield, MANPI 1528069887

Payments from drug & device makers

$16,382in general payments, 2019–2025

Across 887 payments — averaging $18.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • UCB, Inc.$928
  • Acadia Pharmaceuticals Inc$826
  • Teva Pharmaceuticals USA, Inc.$797
  • Novartis$687
  • Lilly USA, LLC$610
  • plus $10K from 50 others

What the payments were for

  • Speaking & faculty fees$1931%
  • Food & beverage$15,97097%
  • Education$2201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)156$2,376
UCB, Inc.37$928
Acadia Pharmaceuticals Inc48$826
Teva Pharmaceuticals USA, Inc.54$797
Novartis38$687
Lilly USA, LLC35$610
Biogen32$582
Sanofi29$577
EMD Serono, Inc.29$545
Amgen(2 entities)20$542
Neurocrine Biosciences, Inc.20$481
CSL Behring19$468
Pfizer28$452
SK Life Science, Inc.17$391
Supernus Pharmaceuticals, Inc.31$367
Grifols USA, LLC19$354
Johnson & Johnson16$341
Amneal Pharmaceuticals LLC16$338
Lundbeck LLC16$334
Biohaven Pharmaceuticals, Inc.15$288
Sunovion Pharmaceuticals Inc.17$278
Kyowa Kirin, Inc.12$250
Biohaven Pharmaceutical Holding Company Ltd.14$248
Acorda Therapeutics, Inc15$243
Eisai Inc.13$225
Tanabe Pharma America, Inc.10$218
Adamas Pharmaceuticals, Inc.12$210
AstraZeneca10$199
MDD US Operations, LLC10$187
Argenx US, Inc.9$183
Alnylam Pharmaceuticals Inc.8$182
GE HealthCare8$156
Ipsen Biopharmaceuticals, Inc6$146
Jazz Pharmaceuticals Inc.6$133
Avanir Pharmaceuticals, Inc.5$120
Genentech USA, Inc.6$102
Medtronic(3 entities)5$98
Mallinckrodt Hospital Products Inc.4$94
E.r. Squibb & Sons, L.L.C.4$89
Akcea Therapeutics, Inc.4$82
Mallinckrodt Enterprises LLC4$79
Bristol Myers Squibb3$69
Arbor Pharmaceuticals, Inc.4$69
Catalyst Pharmaceuticals, Inc.3$59
Livanova USA, Inc.2$58
Neurelis, Inc.2$54
Collegium Pharmaceutical, Inc.2$44
Takeda Pharmaceuticals U.S.A., Inc.2$37
Avion Pharmaceuticals2$36
Shire North American Group Inc2$30
Otsuka America Pharmaceutical, Inc.2$28
Almatica Pharma LLC1$25
Scilex Pharmaceuticals Inc.2$23
Alfasigma USA, Inc.1$20
Assertio Therapeutics, Inc.1$18
Promius Pharma LLC1$11

How this compares

$16,382 in reported general payments places this provider in the 70th percentile of 761 neurology providers in Massachusetts.

See all neurology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$219,936
Medicare patients
379
Services billed
16,430

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ApokynApomorphine Hcl11$365,807
Nurtec OdtRimegepant Sulfate56$108,164
IngrezzaValbenazine Tosylate11$87,594
UbrelvyUbrogepant57$76,625
Ajovy AutoinjectorFremanezumab-Vfrm48$44,360
Emgality PenGalcanezumab-Gnlm56$40,207
Aimovig AutoinjectorErenumab-Aooe54$39,635
SavellaMilnacipran Hcl25$21,480
LyricaPregabalin23$21,032
Zolmitriptan47$18,295
QuliptaAtogepant16$17,886
RytaryCarbidopa/Levodopa12$16,439
Emgality SyringeGalcanezumab-Gnlm17$15,025
Carbamazepine ErCarbamazepine128$14,192
Levetiracetam301$11,504

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt, Lyrica, Dilantin$452$139,978122 claims
AbbVieUbrelvy, Savella, Qulipta$2,376$115,99198 claims
Neurocrine Biosciences, Inc.Ingrezza$481$87,59411 claims
Amneal Pharmaceuticals LLCRytary$338$16,43912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 761 neurology providers in Massachusetts.

Other neurology in Springfield

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →